What АЦЦ инъект treats: Main Uses and Benefits

The primary therapeutic utility of АЦЦ инъект (injectable acetylcysteine) is applied across domains where additional symptomatic support is needed, spanning urgent toxicology management and the support of severe respiratory conditions. This medication is generally considered relevant for individuals who have experienced an acute ingestion of potentially toxic amounts of acetaminophen (paracetamol), and for addressing severe muco-obstructive symptoms present in conditions like chronic bronchitis and cystic fibrosis.

The primary benefit in acute toxicity may assist in managing symptoms linked to organ-specific functional stress and supports the patient during an episode of heightened systemic burden. In respiratory care, the therapeutic benefit supports the patient's ability to clear thick, tenacious phlegm from the airways.

Quick Fact: Supportive Management for Severe Airway Congestion

---

Supporting Acute Ingestion in Drug Toxicity

This medication is commonly applied in clinical settings that involve acute or unstable symptom patterns related to systemic imbalance, providing supportive relief when symptoms interfere with routine activities.

---

Addressing Severe Congestion in Chronic Lung Disease

АЦЦ инъект is relevant in conditions characterized by periods of heightened symptoms, and may be applied in addressing symptom clusters that interfere with daily functioning.

Eligibility Map: Who Can and Cannot Use АЦЦ Инъект — Official Regulatory Information

The eligibility for АЦЦ инъект (injectable acetylcysteine) is determined by regulatory guidelines concerning patient demographics, existing conditions, and allergies.

---

Eligibility Scope

Classification	Population Rule	Status
Contraindicated	Patients with known hypersensitivity to acetylcysteine or any component in the preparation.	Must Not Use
Pediatric Use	Eligible for children weighing 5 kg or greater; safety and efficacy have not been established in children weighing less than 5 kg.	Conditional/Limited
Conditional Use	Patients with a history of asthma or bronchospasm require caution.	Caution Required
Fluid Restriction	Reduced total volume is required for pediatric patients weighing less than 40 kg and patients requiring fluid restriction.	Restriction Required
Pregnancy Status	Permitted only if clearly needed (US Classification: Category B).	Conditional Use
Lactation Status	Breastfeeding is not advised during or immediately following use, due to lack of data on excretion into milk.	Not Recommended

---

Summary of Official Eligibility

The regulatory profile prohibits use based on a single absolute contraindication—a known allergy to the drug. Eligibility is primarily structured by minimum weight thresholds for children and specific conditional restrictions related to fluid balance and respiratory history. These rules, established by governmental authorities, define the precise patient populations for whom the medicine is permitted, restricted, or prohibited.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for injectable Acetylcysteine (АЦЦ инъект) as defined by government regulatory agencies.

---

Documented Pharmacodynamic and Adsorptive Interactions

Interaction Type	Interacting Substance	Official Description of Interaction Outcome
Pharmacodynamic Potentiation	Organic Nitrates (e.g., Nitroglycerin)	Co-administration may potentiate the vasodilator effects, leading to an increased risk of hypotension (low blood pressure).
Adsorptive Interference	Activated Charcoal	The substance is documented to reduce the exposure of oral acetylcysteine due to physical adsorption, necessitating a timing separation rule for the oral form. This interaction does not apply to the intravenous route (АЦЦ инъект).

---

Pharmacokinetic and Regulatory Context

Regulatory prescribing information notes specific pharmacokinetic alterations in certain populations. In subjects with severe liver damage, the clearance of acetylcysteine is officially documented to decrease by 30%, and the terminal half-life is increased by 80% compared to control groups.

It is important to note that official government labeling explicitly states that no dedicated drug-drug interaction studies have been conducted to formally assess metabolic or transporter-based interactions, such as those involving CYP enzymes. Therefore, official data on these specific pharmacokinetic interactions is absent from the regulatory profile.

Mechanism of Action: How АЦЦ инъект Works

Direct Chemical Mucolysis and Airway Clearance

The drug's mechanism involves a primary, rapid chemical action. The active ingredient, N-acetylcysteine (NAC), functions as a direct reductant via its free sulfhydryl group (-SH). This group chemically cleaves the disulfide bonds that heavily cross-link mucoprotein polymers, which are responsible for the high viscosity of respiratory secretions. This process results in the liquefaction of the thick mucus, facilitating its clearance and contributing to the physical expulsion of secretions from the airways.

Cellular Redox Modulation via Glutathione Synthesis

NAC operates as a prodrug, metabolized to L-cysteine, which is the rate-limiting precursor for the synthesis of reduced glutathione (GSH). By replenishing intracellular GSH stores, this restoration stabilizes cellular redox balance and increases the cellular capacity to neutralize oxidative stress in affected tissues. The increased GSH capacity influences key signaling pathways, including those like Nuclear Factor-kappa B (NF-κB), by altering the cellular redox state. This modulation leads to a measurable decrease in the transcription of pro-inflammatory genes, thereby modulating the subsequent inflammatory cascade in the respiratory tract.

Administration of АЦЦ инъект (Acetylcysteine Injection)

АЦЦ инъект (Acetylcysteine Injection) is administered via the intravenous (IV) route as an infusion in a clinical setting, typically as part of a three-stage regimen over a 21-hour period.

---

Administration Scope

Detail	General Requirement
Route of Administration	Intravenous infusion. (Deep intramuscular injection is sometimes documented).
Timing in relation to meals	Not specified in relation to meals.
Missed-dose Rules	A specific procedure for restarting or adjusting the regimen should be determined by a physician based on clinical factors and the original ingestion time.

---

Dosing and Preparation (21-Hour Intravenous Regimen)

The total dose administered over 21 hours is 300 mg/kg of body weight. The injection requires dilution before administration because it is a hyperosmolar solution.

Dose Stage	Dose (mg/kg)	Infusion Duration	Diluent
First Infusion (Loading)	150 mg/kg	1 hour	5% Dextrose in Water or 0.9% Sodium Chloride
Second Infusion	50 mg/kg	4 hours	5% Dextrose in Water or 0.9% Sodium Chloride
Third Infusion	100 mg/kg	16 hours	5% Dextrose in Water or 0.9% Sodium Chloride

---

Age-Specific Rules and Procedural Steps

• Pediatric Administration: Children are treated with the same weight-based doses as adults. However, the total volume of intravenous fluid used for dilution must be modified to account for the patient's age and weight to mitigate the risk of fluid overload.
• Preparation Requirement: The drug must be diluted immediately prior to use; the prepared solution must be used within a few hours to maintain stability.
• Procedural Condition: Administration must be continuous, using an infusion pump for accurate rate control, with all three doses given sequentially.

Research Evidence / Overview of Studies for АЦЦ инъект

Evidence for Use in Treating Paracetamol (Acetaminophen) Overdose

This section summarizes the research studies that have investigated АЦЦ инъект (which contains Acetylcysteine). Research has explored its administration in a hospital setting to investigate patterns related to outcomes impacting the liver and other systemic outcomes related to functional imbalance. Studies conducted in settings with acute episodes have examined how the timing of treatment may influence patient-reported outcomes. Research explored patterns related to physiological strain or stress following treatment. The data show patterns related to the timing of administration. Uncertainty remains regarding the optimal approach for very late presentations or in specific scenarios where initial blood concentrations are unclear.

---

Evidence for Use in Conditions with Excessive Mucus

Research has examined the patterns related to the use of АЦЦ инъект in conditions characterized by fluctuating or episodic manifestations, such as chronic bronchitis where thick, excessive mucus is present. Studies have explored how symptoms evolved in the observed populations, particularly outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Research described how patient-reported outcomes related to perceived discomfort evolved during the study period. However, comparative evidence examining this medicine against other available approaches remains insufficient. Follow-up durations were limited in many studies exploring this use.

---

Long-Term Studies and Follow-up

Long-term effects are not fully established. For the overdose indication, follow-up durations were primarily focused on the immediate period to ensure patient safety and stabilization, and less data are available on very long-term outcomes years later. For the mucus-thinning indications, research exploring how symptoms change over time has primarily focused on short-term or episodic symptom patterns, meaning there is limited information for long-term outcomes and durability of response.

---

Evidence in Special Populations

Research was evaluated in certain special populations. For the overdose indication, studies in children explored patterns related to systemic or functional imbalance. Sample sizes were modest in some research. Evidence in special populations is limited. Data for groups such as pregnant or breastfeeding populations and older adults with significant existing health issues remain insufficient.

---

What is Still Uncertain About АЦЦ инъект

Certainty remains low regarding the long-term effects of repeated or chronic use. Evidence for certain groups, such as those with specific concurrent medical conditions, remains insufficient, and comparative evidence is lacking to definitively say how this medicine may compare to all other alternative treatments. Findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain.

Key Studies & References

1. N-Acetylcysteine - StatPearls - NCBI Bookshelf (Overview of indications, efficacy, and dosing regimens)
2. Treatment of Paracetamol Overdose - NHS Clinical Guideline (Informs on timing, pediatric use context, and uncertainty)

Common questions about АЦЦ инъект (FAQ)

---

Q: What determines the choice between the ACC injekt injection and other forms like tablets or syrups?

The injectable form is intended for urgent, acute conditions managed in a hospital setting, such as an overdose. The intravenous route is selected to allow for rapid and high systemic absorption of the active substance, acetylcysteine, in urgent clinical scenarios. Other forms, such as oral tablets or syrups, are generally utilized in different medical conditions and purposes.

Q: Is ACC injekt the same as generic acetylcysteine in ampoules, or is it a brand-name drug?

ACC injekt is a trade name (brand name) for a sterile solution that contains the active substance acetylcysteine. Acetylcysteine is the common, non-proprietary name, and is available globally in both brand-name and generic injectable formulations. Official documentation identifies acetylcysteine as the primary therapeutic component.

Q: What should be done if an ACC injekt injection is missed?

Regulatory administration rules state that a specific procedure for adjusting or restarting the treatment regimen must be determined by a physician. This is because the drug is typically administered over a specific, sequential time frame (such as a 21-hour regimen) where precise timing is considered critical. Guidance on how to proceed with a missed dose must be obtained from the clinical team managing the treatment regimen.

Q: Is it true that ACC injekt can damage the liver?

The primary, officially approved use of injectable acetylcysteine is to act as an antidote for acetaminophen poisoning, which is a condition intended to protect the liver. Official information does not describe the drug as causing liver damage. However, regulatory data indicates that the clearance of the substance is documented to decrease in subjects who already have severe liver damage.

Q: Why is it important to know that ACC injekt contains sodium?

The sterile injection solution requires dilution, often utilizing 0.9% Sodium Chloride (saline). The total volume and sodium content of the final diluted solution are noted for patients who may have fluid or sodium restrictions. This consideration is particularly relevant for pediatric patients with low body weight, where the volume of fluid needs careful control.

Q: Can ACC injekt be mixed with other solutions for injection?

Official preparation guidelines specify that the product must only be diluted with the recommended solutions, typically 5% dextrose in water or 0.9% sodium chloride, immediately before use. Mixing this product with other medicinal products in the same solution is generally not recommended due to potential risks of chemical incompatibility.

Q: How long can ACC injekt be used so it is not harmful?

The primary official use of the injection (for example, in the case of overdose) involves a short-term, defined regimen, such as a 21-hour treatment course. Information regarding the long-term effects of repeated or chronic use beyond the acute course is limited in regulatory studies. Follow-up durations in research were primarily focused on immediate safety and stabilization.

Q: Does ACC injekt affect heart function or blood pressure?

Official safety documents indicate that cardiovascular effects are among the reported adverse reactions. Tachycardia (a fast heart rate) is reported as a common side effect. Hypotension (low blood pressure) is also documented as a rare or serious adverse reaction.

Q: Does ACC injekt need to be stored in the refrigerator?

Unopened vials of ACC injekt must be stored at a temperature not exceeding 25 C (controlled room temperature) and must be protected from light. Once the solution is prepared for infusion (diluted), the administration must commence within a few hours to maintain stability.

Q: How quickly does ACC injekt start acting in the body?

The intravenous route of administration is specifically chosen to facilitate rapid and high systemic absorption of the active substance. Official pharmacokinetic data indicates that the terminal half-life—the time required for the concentration to fall by half—is documented as approximately 5.6 hours in adults, which suggests a relatively short duration of systemic presence.

Q: Does ACC injekt affect sleep or the nervous system?

Official safety documents report effects on the nervous system as uncommon adverse reactions. These documented effects include drowsiness (feeling sleepy), headache, and tinnitus (ringing in the ears).

Q: Does food intake affect the action of ACC injekt?

The official administration guidelines for the intravenous form of the drug do not specify any special considerations or rules regarding its timing in relation to meals.

The storage and disposal of ACC InjecТ (acetylcysteine injection) must adhere strictly to regulatory conditions to ensure quality and safety.

Official Storage and Stability

The unopened vials must be stored at a temperature not exceeding 25 C and must be kept in the outer carton to protect the medicinal product from light. Once the sterile solution is diluted for intravenous use, administration must commence within 3 hours of preparation, as the product is intended for single use only. Storage must be out of the sight and reach of children.

Disposal Requirements

Any unused medicinal product or waste material must be discarded. Disposal should be carried out in accordance with local requirements established for pharmaceutical waste. The instruction is to discard any unused solution remaining after a single use.